This pioneering study explored the clinical efficacy of combining the HER2-targeting antibody-drug conjugates (ADC) RC48 with the PD-1 inhibitor toripalimab in patients with advanced HER2-positive and HER2 low-expressing GC. This evidence concerns the gene ERBB2 and gastric cancer.